Ready to con­sum­mate its Shire buy­out, Take­da plans US dual list­ing while NYSE los­es a ma­jor phar­ma to Nas­daq

Tak­ing an­oth­er step in Take­da’s as­cent in­to the top rank of glob­al in­dus­try play­ers, ex­ecs at the Japan­ese drug­mak­er say that by the time they com­plete their $62 bil­lion ac­qui­si­tion of Shire, the new com­pa­ny will be trad­ing on the NYSE.

Take­da — which will keep its pri­ma­ry list­ing on the Tokyo Stock Ex­change, where it has trad­ed since 1949 — will pub­licly de­but in New York on Christ­mas Eve this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER